{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:49:45Z","timestamp":1777420185410,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles published in English between January 1985 and September 13, 2023, related to pharmacology, safety, efficacy, and clinical trials were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>A phase II trial compared SUL-DUR with placebo with imipenem and cilastatin in both groups. Overall treatment success in the microbiological intention-to-treat analysis was reported in 76.6% of patients in the SUL-DUR group compared with 81% patients in the placebo group. A phase III trial compared SUL-DUR with colistin in adults with confirmed CRAB infections. Patients received either SUL-DUR or colistin and background therapy with imipenem-cilastatin. SUL-DUR was noninferior to colistin for 28-day all-cause mortality (19% vs 32.3%, treatment difference \u221213.2%; 95% CI [\u221230.0 to 3.5]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Clinicians have limited options to treat CRAB infections. SUL-DUR has demonstrated efficacy against CRAB in patients with pneumonia and may be considered a viable treatment option. Nonetheless, potential impact of concomitant imipenem-cilastatin as background therapy on clinical trial findings is unclear. Further studies are needed to elucidate the role of SUL-DUR alone or in combination with other active antimicrobials for the treatment of CRAB infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>SUL-DUR has shown to be predominantly noninferior to alternative antibiotics in the treatment of pneumonias caused by CRAB, making it a viable treatment option. Further postmarketing data is needed to ascertain its role in other infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231204566","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:46:03Z","timestamp":1696992363000},"page":"735-741","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    Infections"],"prefix":"10.1177","volume":"58","author":[{"given":"Benjamin","family":"August","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Henry Ford Hospital, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8680-4572","authenticated-orcid":false,"given":"Andrew","family":"Matlob","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini B.","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Ascension St. John Hospital, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"bibr1-10600280231204566","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040205"},{"key":"bibr2-10600280231204566","unstructured":"Centers for Disease Control and Prevention. 2019 Antibiotic resistance annual threats report. November 21, 2021. Accessed August 25, 2023. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"bibr3-10600280231204566","unstructured":"Centers for Disease Control and Prevention. Carbapenem resistant\n                      Acinetobacter\n                      . Accessed August 25, 2023. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/acinetobacter-508.pdf"},{"key":"bibr4-10600280231204566","unstructured":"Centers for Disease Control and Prevention. 2022 special report: COVID-19 U.S. impact on antimicrobial resistance. Accessed August 25, 2023. https:\/\/www.cdc.gov\/drugresistance\/pdf\/covid19-impact-report-508.pdf"},{"key":"bibr5-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30156"},{"key":"bibr6-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"bibr7-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01665-09"},{"key":"bibr8-10600280231204566","unstructured":"Innoviva Specialty Therapeutics, Inc. Xacduro (sulbactam-durlobactam). Accessed August 25, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216974Orig1s000Correctedlbl.pdf"},{"key":"bibr9-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01612-17"},{"key":"bibr10-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14"},{"key":"bibr11-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.3.494"},{"key":"bibr12-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1035-1040.2000"},{"key":"bibr13-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.012"},{"key":"bibr14-10600280231204566","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974"},{"key":"bibr15-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"bibr16-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"bibr17-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00794-19"},{"key":"bibr18-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00071-20"},{"key":"bibr19-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"bibr20-10600280231204566","doi-asserted-by":"publisher","DOI":"10.2165\/11594090-000000000-00000"},{"key":"bibr21-10600280231204566","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070769"},{"key":"bibr22-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0636-7"},{"key":"bibr23-10600280231204566","unstructured":"U.S. Food and Drug Administration. FDA briefing document NDA 216974. Division of anti-infectives\/office of infectious diseases. Accessed August 25, 2023. https:\/\/www.fda.gov\/media\/167096\/download"},{"key":"bibr24-10600280231204566","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S332160"},{"key":"bibr25-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad094"},{"key":"bibr26-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"bibr27-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00422-X"},{"key":"bibr28-10600280231204566","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070880"},{"key":"bibr29-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa421"},{"key":"bibr30-10600280231204566","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01213-x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231204566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231204566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231204566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:22Z","timestamp":1777374802000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231204566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/10600280231204566"],"URL":"https:\/\/doi.org\/10.1177\/10600280231204566","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}